- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | 203 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| 14.01. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | Woori IO shareholders approve final step in OSR Holdings acquisition | 4 | Investing.com | ||
| 19.12.25 | Woori IO-Aktionäre stimmen Übernahme durch OSR Holdings zu | 2 | Investing.com Deutsch | ||
| 19.12.25 | OSR Holdings Inc.: Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings | 351 | PR Newswire | Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university
... ► Artikel lesen | |
| 04.12.25 | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement | 393 | Newsfile | New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month... ► Artikel lesen | |
| 25.11.25 | OSR Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.11.25 | OSR Enterprises Acquires MAISENSE To Expand Next-Generation AI Compute Capabilities | 2 | pulse2.com | ||
| 25.11.25 | EQS-News: OSR Enterprises AG: Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD bekannt, einem Hyperscale-Plasmonik-SoC-Unternehmen | 441 | EQS Group (DE) | EQS-News: OSR Enterprises AG
/ Schlagwort(e): Fusionen & Übernahmen
Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD... ► Artikel lesen | |
| 21.11.25 | Potenzieller Lizenzdeal für Krebstherapie katapultiert OSR Holdings-Aktie nach oben | 5 | Investing.com Deutsch | ||
| 14.11.25 | OSR Holdings names Vaximm co-founder as CEO of subsidiary | 5 | Investing.com | ||
| 14.11.25 | OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion | 167 | PR Newswire | BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm... ► Artikel lesen | |
| 12.11.25 | OSR Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10.25 | "You'll get nothing": OSR CEO's message sparks employee revolt amid collapse | 9 | CTech | ||
| 20.10.25 | Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target | 352 | Newsfile | New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month... ► Artikel lesen | |
| 16.10.25 | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | OSR Holdings announces definitive agreement to acquire Woori IO | 6 | Seeking Alpha | ||
| 14.10.25 | OSR Holdings übernimmt südkoreanischen Spezialisten für nicht-invasive Blutzuckermessung | 3 | Investing.com Deutsch | ||
| 14.10.25 | OSR Holdings to acquire noninvasive glucose monitoring firm Woori IO | 1 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,166 | +1,55 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,798 | -2,84 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| CAPRICOR | 19,440 | -0,51 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| CORMEDIX | 6,650 | +3,10 % | Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? | ||
| MINERVA NEUROSCIENCES | 3,360 | -7,69 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 | BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 6,200 | -0,80 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,130 | -1,52 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,380 | 0,00 % | Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed private placement led by Samsara BioCapital... ► Artikel lesen | |
| IO BIOTECH | 0,326 | +4,93 % | Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals | LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 16,800 | +2,82 % | Alto Neuroscience, Inc.: Alto Neuroscience to Participate in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| QIAGEN | 45,485 | -2,04 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| CG ONCOLOGY | 55,10 | +3,38 % | What Analysts Are Saying About CG Oncology Stock | ||
| PRAXIS PRECISION MEDICINES | 314,75 | +7,04 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines |
Das Unternehmen OSR HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,692 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.